426219-18-3

Basic information

• Product Name: TAK-700
• Synonyms: (S)-6-(7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-e]imidazol-7-yl)-N-methyl-2-naphthamide;6-[7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl]-N-methyl-2-naphthalenecarboxamide TAK-700 (Orteronel);6-(6,7-dihydro-7-hydroxy-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methyl-2-Naphthalenecarboxamide;6-(6,7-dihydro-7-hydroxy-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methy;6-[7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl]-N-methyl-2-naphthalenecarboxamide
• CAS NO: 426219-18-3
• Molecular Formula: C18H17N3O2
• Molecular Weight: 307.34648
• Product Categories: Inhibitors;Inhibitor
• Mol File: 426219-18-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TAK-700(CAS DataBase Reference)
• NIST Chemistry Reference: TAK-700(426219-18-3)
• EPA Substance Registry System: TAK-700(426219-18-3)

Safety Data

• Hazardous Substances Data: 426219-18-3(Hazardous Substances Data)

Usage

General Description

TAK-700, also known as orteronel, is a selective inhibitor of 17α-hydroxylase/C17,20-lyase (CYP17). It is a synthetic, nonsteroidal, androgen biosynthesis inhibitor that is used in the treatment of advanced prostate cancer. TAK-700 works by decreasing the production of androgens, which are hormones that can stimulate the growth of prostate cancer cells. Additionally, TAK-700 has shown promising results in clinical trials and is being studied for its potential use in other hormone-related cancers, such as breast and ovarian cancer. However,

Upstream product

• 426219-43-4 5,6-dihydro-7H-pyrrolo[1,2-c]imidazol-7-one 
• 566200-77-9 6-[1,3-dihydroxy-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methyl-2-naphthamide 
• 109-72-8 n-butyllithium 
• 1346155-60-9 6-(7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N,N-diisopropyl-2-naphthamide 
• 426219-35-4 6-bromo-N-methyl-2-naphthamide 
• 392-83-6 o-trifluoromethylphenyl bromide 
• 426219-46-7 6-bromo-N,N-diisopropyl-2-naphthamide 
• 1346155-54-1 N,N-diisopropyl-6-[1-hydroxy-1-(1-trityl-1H-imidazol-4-yl)methyl]-2-naphthamide 
• 426219-47-8 N,N-diisopropyl-6-[(1-trityl-1H-imidazol-4-yl)carbonyl]-2-naphthamide 
• 74-89-5 methylamine 
• 1346155-45-0 3-bromo-1-(1H-imidazol-4-yl)-1-propanone hydrobromide 
• 57531-35-8 C₆H₆N₂O 
• 5773-80-8 6-bromo-2-naphthoic acid 
• 87700-60-5 6-bromonaphthalene-2-carbonyl chloride 

Downstream Products

• 566939-85-3 Orteronel 
• 752243-39-3 6-(7-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methylnaphthalene-2-carboxamide 
• 426219-53-6 2C₁₀H₁₁NO₅*C₁₈H₁₇N₃O₂ 

Relevant articles and documents

1,1-Diarylalkenes as anticancer agents: Dual inhibitors of tubulin polymerization and phosphodiesterase 4

A series of 1,1-diarylalkene derivatives were prepared to optimize the properties of CC-5079 (1), a dual inhibitor of tubulin polymerization and phosphodiesterase 4 (PDE4). By using the 3-ethoxy-4-methoxyphenyl PDE4 pharmacophore as one of the aromatic ri

Novel imidazole derivatives, production method thereof and use thereof

The present invention provides a compound having a steroid C17,20-lyase-inhibitory activity and useful for the therapy and prophylaxis of tumor such as prostatism, breast cancer and the like, and a method for efficiently separating an optically active compound of this compound from a mixture of optical isomers thereof, a compound of the formula: wherein each symbol is as defined in the specification, a salt thereof or a prodrug thereof, and a method for obtaining an optically active compound by optically resolving a mixture of optical isomers by the use of a resolving agent such as tartranilic acid and the like.